PURPOSE: Anastomotic recurrence after an anterior resection for rectal cancer has not been analyzed in detail in the era of total mesorectal excision. This study tried to clarify the characteristics of patients with anastomotic recurrence when compared to the pelvic recurrence. METHODS: This study compared the clinicopathological data of 21 isolated recurrent patients that were treated between 1998 and 2007, including eight with anastomotic recurrence and 13 with pelvic recurrence. RESULTS: The rate of positive serum carcinoembryonic antigen level at the time of recurrence is 0% in the anastomotic recurrence group and 85% in the pelvic recurrence group (p < 0.001). The clinical symptoms presented in 13% in the anastomotic recurrence group, in comparison to 69% in the pelvic recurrence group (p = 0.024). The median time from the initial resection until recurrence was 14 months in the anastomotic recurrence group, whereas it was 12 months in the pelvic recurrence group (p = 0.992). The survival rate of patients with anastomotic recurrence was higher than those with pelvic recurrence (p = 0.005). CONCLUSION: A difference was observed in the serum carcinoembryonic antigen, clinical symptom, and survival between patients with anastomotic and pelvic recurrence. Furthermore, according to these results, we should pay attention to these clinical features in the follow-up period.
PURPOSE: Anastomotic recurrence after an anterior resection for rectal cancer has not been analyzed in detail in the era of total mesorectal excision. This study tried to clarify the characteristics of patients with anastomotic recurrence when compared to the pelvic recurrence. METHODS: This study compared the clinicopathological data of 21 isolated recurrent patients that were treated between 1998 and 2007, including eight with anastomotic recurrence and 13 with pelvic recurrence. RESULTS: The rate of positive serum carcinoembryonic antigen level at the time of recurrence is 0% in the anastomotic recurrence group and 85% in the pelvic recurrence group (p < 0.001). The clinical symptoms presented in 13% in the anastomotic recurrence group, in comparison to 69% in the pelvic recurrence group (p = 0.024). The median time from the initial resection until recurrence was 14 months in the anastomotic recurrence group, whereas it was 12 months in the pelvic recurrence group (p = 0.992). The survival rate of patients with anastomotic recurrence was higher than those with pelvic recurrence (p = 0.005). CONCLUSION: A difference was observed in the serum carcinoembryonic antigen, clinical symptom, and survival between patients with anastomotic and pelvic recurrence. Furthermore, according to these results, we should pay attention to these clinical features in the follow-up period.
Authors: Thomas Anthony; Clifford Simmang; Neil Hyman; Donald Buie; Donald Kim; Peter Cataldo; Charles Orsay; James Church; Daniel Otchy; Jeffery Cohen; W Brian Perry; Gary Dunn; Janice Rafferty; C Neal Ellis; Jan Rakinic; Phillip Fleshner; Thomas Stahl; Sharon Gregorcyk; Charles Ternent; John W Kilkenny; Mark Whiteford Journal: Dis Colon Rectum Date: 2004-05-04 Impact factor: 4.585
Authors: Christopher E Desch; Al B Benson; Mark R Somerfield; Patrick J Flynn; Carol Krause; Charles L Loprinzi; Bruce D Minsky; David G Pfister; Katherine S Virgo; Nicholas J Petrelli Journal: J Clin Oncol Date: 2005-10-31 Impact factor: 44.544
Authors: C de Chaisemartin; C Penna; D Goere; S Benoist; A Beauchet; C Julie; B Nordlinger Journal: Colorectal Dis Date: 2008-04-28 Impact factor: 3.788
Authors: F A Calvo; F Rivas; C V Sole; M Gómez-Espí; R Herranz; E Del Valle; M Rodríguez; E Alvarez Journal: Clin Transl Oncol Date: 2013-10-16 Impact factor: 3.405
Authors: M Kruschewski; M Ciurea; S Lipka; S Daum; L Moser; B Meyer; J Gröne; J Budczies; H J Buhr Journal: Langenbecks Arch Surg Date: 2012-06-28 Impact factor: 3.445